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Christophe Mulle 2, Christophe Magnan 3, Matthieu Raoux 1, Jochen Lang 1,*ABSTRACT
Objective: Islets secrete neurotransmitters including glutamate which participate in fine regulation of islet function. The excitatory ionotropic
glutamate receptor GluK2 of the kainate receptor family is widely expressed in brain and also found in islets, mainly in a and g cells. a cells co-
release glucagon and glutamate and the latter increases glucagon release via ionotropic glutamate receptors. However, neither the precise nature
of the ionotropic glutamate receptor involved nor its role in glucose homeostasis is known. As isoform specific pharmacology is not available, we
investigated this question in constitutive GluK2 knock-out mice (GluK2/) using adult and middle-aged animals to also gain insight in a potential
role during aging.
Methods: We compared wild-type GluK2þ/þ and knock-out GluK2/ mice using adult (14e20 weeks) and middle-aged animals (40e52
weeks). Glucose (oral OGTT and intraperitoneal IPGTT) and insulin tolerance as well as pyruvate challenge tests were performed according to
standard procedures. Parasympathetic activity, which stimulates hormones secretion, was measured by electrophysiology in vivo. Isolated islets
were used in vitro to determine islet b-cell electrical activity on multi-electrode arrays and dynamic secretion of insulin as well as glucagon was
determined by ELISA.
Results: Adult GluK2/ mice exhibit an improved glucose tolerance (OGTT and IPGTT), and this was also apparent in middle-aged mice,
whereas the outcome of pyruvate challenge was slightly improved only in middle-aged GluK2/ mice. Similarly, insulin sensitivity was markedly
enhanced in middle-aged GluK2/ animals. Basal and glucose-induced insulin secretion in vivo was slightly lower in GluK2/ mice, whereas
fasting glucagonemia was strongly reduced. In vivo recordings of parasympathetic activity showed an increase in basal activity in GluK2/ mice
which represents most likely an adaptive mechanism to counteract hypoglucagonemia rather than altered neuronal mechanism. In vitro recording
demonstrated an improvement of glucose-induced electrical activity of b-cells in islets obtained from GluK2/ mice at both ages. Finally,
glucose-induced insulin secretion in vitro was increased in GluK2/ islets, whereas glucagon secretion at 2 mmol/l of glucose was considerably
reduced.
Conclusions: These observations indicate a general role for kainate receptors in glucose homeostasis and specifically suggest a negative effect
of GluK2 on glucose homeostasis and preservation of islet function during aging. Our observations raise the possibility that blockade of GluK2 may
provide benefits in glucose homeostasis especially during aging.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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neurotransmitter in the brain, is present in exocytotic peptide-hormone
containing large dense core vesicles as well as synaptic-like micro-
vesicles in a- and b-cells [3e5]. Quantitatively, a-cells seem to be the
most important source of regulated glutamate release [4e6] although
glutamate derived from metabolic pools via reversal of uptake by
membrane glutamate transporters has been proposed to
contribute [7].
Glutamate activates metabotropic receptors, which are coupled to G-
proteins and downstream pathways, or ionotropic receptors, such as
the NMDA-, AMPA- and kainate receptors forming non-selective cation
channels [8]. Isoforms of most of these ionotropic receptors are
expressed to various degrees in islet cells, though at lower levels than
in brain [9]. No major difference exists in mouse as compared to man
concerning the relative distribution between a- and b-cells [10]. The
ionotropic NMDA receptors (GluN1 to 3, gene symbol GRIN1 to 3 [11])
are ligand-gated channels permeable to calcium, and their activity is
highly dependent on voltage [12]. The islet NMDA receptor GluN1 plays
an inhibitory role in glucose-induced insulin secretion and has been
characterized as drug target in diabetes therapy [13e15]. As mem-
brane depolarisation plays a role and high-affinity binding of glutamate
as well as co-activation by the amino acids glycine or serine are
required for NMDA channel opening, these receptors may be saturated
by the prevailing extracellular plasma concentrations of the corre-
sponding amino acids [16]. In contrast, ionotropic AMPA receptors
(GluA1 to 4, gene symbol GRIA1 to 4 [11,17]) and kainate receptors
(GluK1 to 5, gene symbol GRIK1 to 5 [11,17]) are physiologically
stimulated only by glutamate and require higher concentrations of
glutamate similar to those seen locally after release of this amino acid
from islet cells [4,12].
Glutamate activation of islet AMPA and kainate receptors stimulates
secretory cells in an auto- or paracrine manner [4,18e22]. Final
outcome, however, may be more complex; for example, activation of a
variant of the AMPA receptor GluA4 on d-cells leads to secretion of
somatostatin [20], which in turn inhibits a- and b-cells [23,24].
Similarly, activation of a-cell glutamate receptors and ensuing
glucagon release may enhance insulin secretion from b-cells [25].
Subsequent to the initial observation in rodents that activation of a-
cells leads to glutamate release [4], a series of elegant experiments led
to the demonstration of a positive regulatory loop of glucagon release
via co-secreted glutamate through AMPA and/or kainate receptors in
primate islets and its acute functional relevance in vivo in mice [18].
The precise receptor type(s) involved, however, remained unclear, and
pharmacology did not offer specific tools to determine what they were
[11]. At least four of the five kainate receptor subunits are expressed at
the RNA level in murine and human islets, i.e. GluK2 to GluK5 [10]. In
contrast to GluK2 and GluK5, GluK1, GluK3, and GluK4 are present only
at very low or spurious levels in murine or human islets [10,26].
Moreover, GluK2 and 3 can function as homomers, whereas GluK4 and
5 must assemble as obligatory heterotetramers with GluK1, 2, or 3
[27e29]. Therefore GluK2 may be a promising target to investigate the
potential role of kainate receptors in islet physiology as its inactivation
also impedes GluK5 protein expression [30]. Within islets GluK2 is
found mainly on a-cells and on pancreatic polypeptide producing g-
cells [10,26]. Outside islets GluK2 is widely expressed in brain tissue
and is implicated in the fine regulation of the activity of neuronal cir-
cuits by acting at the pre- or postsynaptic side, through either iono-
tropic or metabotropic functions [28]. It has also been implicated in the
propensity to recurrent seizures in chronic epilepsy [28,31]. Except for
a lesser increase in body weight and despite reduced motor activity, no
changes of potentially metabolic origin have been described in GluK2
knock-out mice [31e34].MOLECULAR METABOLISM 30 (2019) 152e160  2019 The Authors. Published by Elsevier GmbH. This is an open
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existing, constitutive knock-out model [25,32,36]. As the mechanisms
involved are expected to concern fine tuning of islet function, but not
basic mechanisms in the control of glucose homeostasis, we hy-
pothesized that changes may become more prominent during aging
and observations in middle-aged mice, in contrast to old mice, may
avoid interference by a general senescence phenotype [37]. For this
reason we investigated both adult and middle-aged mice to test
whether GluK2 may play a role in islet function and glucose
homeostasis.
2. MATERIALS AND METHODS
2.1. Animals and cells
Progeny of the constitutive knock-out C57BL/6 GluK2/ [32,35,36] and
wild-type C57BL/6 mice were bred at the Bordeaux University Animal
House Facility (DAP 04236.01, DAP 15318). C57BL/6J GluK2/ had
been backcrossed 10 times with C57BL/6J and subsequently wild-type
C57BL/6J GluK2þ/þ mice and C57BL/6J GluK2/ mutant litter mice
were obtained by crossing heterozygous mice. Animals were genotyped
by RT-PCR (primers see Supplemental Table 1) using a KAPA Mouse
Genotyping Kit (KAPA Biosystems, Boston, MA, USA). Animals (male)
were used at adult (14e20 weeks) or at middle-aged age (40e52
weeks). All experimental procedures were approved by the Ministry of
Education and Research (no. 04236.01).
2.2. Glucose and insulin tolerance tests, pyruvate challenge, islet
secretion assays, and morphometric analysis
Glucose (OGTT, 3 g/kg; IPGTT 2 g/kg) and insulin tolerance tests (0.5 U/
kg) were performed as described [38,39]. Similarly, glycemia was
measured during an intraperitoneal pyruvate challenge (2 g of pyru-
vate/kg body weight) after overnight fasting (15 h). Islets were obtained
as published [39,40] and cultured overnight in RPMI (containing
11 mM glucose and supplemented with FCS 10%, penistroptomycin
1%, glutamine 1%, HEPES 10 mM, pyruvate 1 mM) at 37 C (5% CO2,
>90% relative humidity) in 96-well filter plates (multiscreen Durapore
BV1.2 mm; Millipore, Molsheim, France). Dynamic insulin and glucagon
release was assayed as published [41]. Blood glucose concentrations
were determined with ACCU-CHEK (Roche). Pancreatic mass and a/b
cell mass were measured on isolated whole pancreas as described
previously [42] and further detailed in the legend to Figure S1.
2.3. In vivo recordings of parasympathetic activity
Parasympathetic activity was recorded at the thoracic branch of the
vagus nerve, along the carotid artery as described previously [43].
Unipolar nerve activity was recorded continuously for 15 min during
fasting state and after an intraperitoneal injection of glucose (2 mg/kg)
during 15 min. Data were digitized with PowerLab/4sp digitizer
(ADinstruments, Paris, France). Signals were amplified 105 times and
filtered using low- and high-frequency cut-offs of 100 and 1000 Hz
and monitored using the Chart 4 computer program (ADinstruments,
Paris, France).
2.4. Islet isolation, cell culture, electrophysiology and signal
analysis, immunofluorescence
Electrophysiological recordings were performed according to published
methods [44e46]. Mice islets were prepared and seeded on micro-
electrode arrays (MEA, 60 electrodes; MCS, Reuttlingen, Germany).
Four days later, signals were recorded (10 kHz) and analyzed offline in
terms of frequency with commercial software (MC_Rack, MCS).
Immunofluorescence was performed on whole islets and dispersedaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 153
Figure 1: Improved glucose tolerance, pyruvate challenge outcome and insulin sensitivity in GluK2/ mice. Given are time courses and the area under the curve (AUC). (a, b)
Intraperitoneal Glucose Tolerance Test (c, d), Oral Glucose Tolerance Test (OGTT) and (e,f) Intraperitoneal Pyruvate Challenge Test were performed in WT and KO mice, in both adult
and middle-aged animals. (g) Insulin Tolerance Test (0.5 U/kg) was performed in WT (open circles) and KO mice (closed red circles), both in adults and middle-aged. (h) Area under
the curves of g (AUC). Means  SEM; a, c, e and g, t-test; b, d, f and h, ANOVA followed by Tukey post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001 or by Holm-Sidak post-hoc
test, #p < 0.05; N ¼ 7 except for g and h (N ¼ 6).
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Figure 2: Middle-aged GluK2/ mice have reduced basal and glucose-stimulated
insulinemia as wells reduced fasting glucagonemia. (a) Insulin levels in vivo were
lower in KO mice. Means  SEM; N ¼ 7. (b) Fasting glucagonemia is significantly
reduced in middle-aged KO mice. Means  SEM; N ¼ 7. ManneWhitney; * 2p < 0.05,
** 2p < 0.01.islet cells using either a polyclonal rabbit anti-GluK2 antibody (Synaptic
Systems, Goettingen, Germany) [47] or a rabbit monoclonal antibody
(anti-GluR6/7 clone NL9, Merck Millipore) [48] and appropriate sec-
ondary antibodies.
2.5. Statistics
Values are expressed as mean  SEM. D’Agostino-Pearson omnibus
or BrowneForsythe tests were used to test for normality. Comparison
of means was made by tests as indicated in the figure legends using
Prism 7.0 and AUC’s were calculated as values above basal using the
corresponding function in the same software.
3. RESULTS
3.1. GluK2 knock-out improves glucose tolerance and insulin
sensitivity
To obtain a first indication whether the constitutive knock-out of
excitatory GluK2-containing kainate receptors alters glucose homeo-
stasis, we tested glucose tolerance [49] (Figure 1). Intraperitoneal
glucose tolerance tests (IPGTTs) showed a significant decrease in
glucose-tolerance in middle-aged GluK2þ/þ mice as compared to
adult ones (Figure 1A,B). In contrast, an improved tolerance was
evident in adult GluK2/ mice when compared to GluK2þ/þ animals
at time points later than 50 min. This improved glucose handling was
preserved in middle-aged GluK2/ mice (Figure 1A,B). Oral glucose
tolerance tests are more directly influenced by islet function. Using this
test GluK2/ mice showed again an improved tolerance, which was
somewhat less marked than in OGTT but well preserved during aging
(Figure 1C,D). We also examined pyruvate challenge, which reflects
gluconeogenesis in the liver and in other organs [49]. Whereas no
difference was evident between adult wild-type or knock-out mice,
however, a clear improvement in pyruvate challenge tests was
apparent in middle-aged GluK2/ mice as compared to middle-aged
GluK2þ/þ animals (Figure 1E,F). Insulin sensitivity was comparable
among adult GluK2þ/þ or GluK2/ mice and, as expected, sensitivity
deteriorated significantly during aging in wild-type animals
(Figure 1G,H). In stark contrast, in middle-aged GluK2/ mice insulin
sensitivity was well preserved, similar to adult GluK2/ animals and
even slightly better than in adult wild-type mice. In view of the above
described phenotype, we concentrated our investigations on middle-
aged animals. Note that pancreas weight as well as a- or b-cell
volume did not differ among wild-type and knock-out mice (Fig. S1). As
previously reported [32], we observed a smaller weight gain in
GluK2/mice (Fig. S2). Note that we were not able to detect GluK2 by
immunofluorescence in islets in line with their low expression levels in
these tissues (data not shown). Collectively, these data suggest a
remarkable preservation of glucose handling in GluK2/ mice during
aging.
3.2. Knockout of GluK2 reduces fasting glucagonemia and
increases parasympathetic nerve activity
We next tested insulin and glucagon blood levels either after a glucose
challenge or at the fasting state (Figure 2). Basal insulin levels were
lower in GluK2/ mice in vivo as well as 30 min after intraperitoneal
glucose injection in line with the improved glucose handling and insulin
sensitivity observed in Figure 1. Interestingly we also observed a
significant reduction in fasting glucagon levels in GluK2/ mice as
compared to wild-type animals.
In vivo islet function is influenced by the central nervous system via
the parasympathetic vagus nerve, which stimulates insulin and
glucagon secretion [50], and its efferent branch is activated upon anMOLECULAR METABOLISM 30 (2019) 152e160  2019 The Authors. Published by Elsevier GmbH. This is an open
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decrease in plasma glucagon levels may be due to a reduced para-
sympathetic activity in knock-out animals. Recordings of electrical
activity in fasted wild-type mice showed a clear increase in nerve
activity when glucose levels were increased via a glucose injection
(Figure 3). Contrary to our expectations, in GluK2/ mice, electrical
activity was already significantly elevated in the fasted state and
glucose injections did only led to a minor additional increase
(Figure 3).
3.3. Knockout of GluK2 preserves electrical in vitro activity of islets
during aging
The in vivo phenotyping presented above begs the question whether
in vitro islet function may be altered in GluK2/ mice. We first
examined electrical activity of islets cells by extracellular recordings
using microelectrode arrays. Under the conditions used the recording
of so-called slow potentials reflects biphasic activity of b-cells and
depends strictly on glucose concentrations applied [40,46,53e55].
Note that this approach does not capture electrical activity of a-cells as
most likely they are not coupled and henceforth electrical signals are
too small. As can be seen in Figure 4A,C, an increase in glucose from 3
to 8.2 mM induces a vigorous electrical activity in islets prepared from
adult wild-type GluK2þ/þ mice. Note that a distinct first phase is not
always clearly visible here as means are given and activation may not
be completely in phase in between the different islets on the same
micro-electrode array. Islets from adult GluK2/ mice had a signifi-
cantly higher level of activity (Figure 4A,C). This is evident during the
first and even more pronounced during the second phase of glucose
stimulation. Most importantly this difference between GluK2þ/þ and
GluK2/ mice was fully conserved during aging (Figure 4B,D) and
suggests that disruption of the gene encoding GluK2 improved
glucose-induced electrical coupling of b-cells during the first and the
second phase of islet activity.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 155
Figure 3: Middle-aged GluK2/ mice have an increased electrical activity of the parasympathetic nerve in the fasted state. (a) Electrical signals of in vivo recordings during
fasting state and after an intraperitoneal injection of glucose (2 mg/kg) in middle-aged GluK2þ/þ (WT) or GluK2/ (KO) mice. (b) Statistics. Means  SEM; ANOVA and Tukey’s
post-hoc analysis; *2p < 0.05, ***p < 0.001; N ¼ 3e5.
Brief Communication3.4. Knockout of GluK2 improves glucose-induced insulin secretion
but reduces glucagon secretion in vitro
We finally tested whether this improved activity is also reflected in islet
hormone secretion. To this end, islets from middle-aged animals
(GluK2þ/þ or GluK2/) were superfused with 11 mM, 2 mM, and again
11 mM glucose (Figure 4EeF). Note that cell mass and hormone con-
tents were not significantly different between GluK2þ/þ or GluK2/
islets (see Supplemental Figs. 1 and 3). Islets obtained from GluK2/
mice secreted significantly more insulin during the initial stimulation as
well as during the second stimulus (Figure 4F,G). Note that this obser-
vation is not in contradiction to the data obtained in vivo where insulin
secretion is also determined by insulin sensitivity. In contrast, glucagon
secretion at 2 mM glucose was largely reduced in GluK2/
(Figure 4H,K). Glucagon secretion was distinctive biphasic under the
conditions used here, a phenomenon often observed when stimulations
by arginine are used but also described previously for glucose in
perfused pancreas [56,57] and in islets [58,59].
4. DISCUSSION
Glucose homeostasis is fine-tuned by neurotransmitter actions in the
nervous system and locally within the pancreatic islets [1,60]. Major
findings in our study on the knock-out of the excitatory kainate receptor
subunit GluK2 were an improved glucose tolerance characterized by
reduced glucagon release, increased insulin sensitivity, and enhanced
insulin secretion in vitro as well as absence of the decline in these
functions normally encountered during aging. The normal aspect of
islets in terms of mass and a/b-cell volumes suggests the absence of
any major developmental abnormality. Collectively, these data suggest
that GluK2, which finely tunes the activity of neuronal circuits [28] and
which has previously been implicated in recurrent epileptic seizures
[31,34], autism [61], and cognitive abilities [62], exerts a wider bio-
logical role such as in glucose homeostasis.
Obviously, a major limitation of our study is the use of a constitutive
knock-out and we can thus not pinpoint precisely the anatomical156 MOLECULAR METABOLISM 30 (2019) 152e160  2019 The Authors. Published by Elsevier GmbH. Trelevant site or sites. Indeed, the homeostatic effect observed here
may be mediated by a peripheral action within the islet as well as a
central action on neural regulation. Glutamatergic neurotransmission
intervenes in regulation of glucose homeostasis, mainly investigated
in the context of counterregulatory responses to hypoglycaemia [63],
but the precise structures and connections are still far from being
elucidated. In this context glutamate plays a role in ventromedial
hypothalamic neurons [64] and via kainate receptors in the dorsal
motor nucleus of the vagus that regulates stimulatory para-
sympathetic output to the islets [65]. Thus the increased electrical
activity of the vagus observed here may reflect an altered excitatory
output to islet a- and b-cells in the GluK2/ mice. However,
increased vagal activity should enhance islet hormone secretion
in vivo but was accompanied here by reduced glucagon levels in vivo.
Thus, the increased vagus activity more likely reflects a counter-
regulatory adaptation to the reduced a-cell activity, which we
observed in vivo and in vitro in isolated islets.
The improved glucose tolerance clearly has several components. Note
that differences in locomotor activity may obviously confound the
metabolic situation. Although such a reduction has been described by
one group [66], it was not found in our colony [33]. A difference in
weight between wild type and knockout mice was observed here and
in an earlier study [32] throughout all ages and is expected to improve
glucose tolerance. However, insulin sensitivity was comparable in adult
mice, thus at a stage where improved electrical b-cell activity was
already present in vitro. This points at least to a sizeable contribution of
islet mechanisms to the phenotype.
Different intra-islet glutamate effects on glucagon secretion have been
described. At low glucose, glutamate, AMPA, or kainate stimulates a-
cell glucagon secretion but not insulin release [18,19,22,25]. Note that
one study reported an inhibitory effect of glutamate on glucagon
secretion in rat islets via a metabotropic glutamate receptor (mGluR4,
gene symbol GRM4) [67]. Similarly, glutamate may activate d-cells
[20] and the ensuing release of somatostatin may reduce a-cell ac-
tivity, but this should occur at elevated levels of glucose [23].his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Increased glucose-induced islet b-cell activity in adult and middle aged GluK2/ mice. (aec) Electrical activity of islets was recorded in vitro on microelectrode arrays
at 3 and 8.2 mM glucose. (a, b) Given are means and SEM of average slow potential frequency per mice (GluK2þ/þ, WT; GluK2/, KO; N ¼ 4 independent preparations of mouse
islets for each condition in adult (a) or middle aged (b) mice). (c, d) Areas under the curve (AUC) for first phase (5e15 min) and second phase (25e50 min). Given are means  SD,
N ¼ 4 independent islet preparations and assays representing analysis of 126e183 islets for each condition (WT and KO, adult (c) or middle aged (d) mice). ManneWhitney test;
****, 2p < 0.0001. (e) Glucose perfusion pattern (as used in f and h); initial perfusion at 11 mM glucose was reduced to 2 mM and subsequently raised again to 11 mM. (f) Insulin
release (as glucose induced insulin secretion in regard to the value at 3 mM glucose at 60 min) for middle aged GluK2þ/þ (WT) and GluK2/ (KO) mice. (g) Area under the curves
for insulin (AUC, t ¼ 82e110 min). Means  SEM. (h) Glucagon release (as fold stimulation in regard to value at 11 mM glucose at 50 min) for middle-aged GluK2þ/þ (WT) and
GluK2/ (KO) mice. (k) Area under the curves for glucagon (AUC, t ¼ 55e80 min). (fek) Means  SEM; N ¼ 3 independent islet preparations and assays; t-test; * 2p < 0.05; **
2p < 0.01. Hormone contents did not differ significantly between islets from WT and KO animals (see Supplemental Fig. S3).
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Brief CommunicationIn contrast, there is considerable evidence for a stimulatory autocrine
feedback loop of glutamate in a-cells [4,18,20]. The obvious question
is whether GluK2 may be specifically implicated. As a-cells express
AMPA as well as kainate receptors, and both are difficult to distinguish
in pharmacological terms, the molecular identity of the relevant re-
ceptors has hitherto only been addressed indirectly. Although previous
reports favor a functional role of AMPA rather than of kainate receptors
[19], caution should be exerted. Isolated a-cells may behave differently
from cells within islets, as actually observed by the authors [19], and
these findings do not preclude a role of kainate receptors specifically in
the autocrine stimulation of glucagon secretion. The situation is even
more complex in view of the reported metabotropic action of kainate
receptors which may imply GluK2 [68e70]. Such a metabotropic
action may not be detected in electrophysiological recordings. Finally it
is also of note that antagonist used in this [19] as well as in other
studies [22,25] are only partially specific at best [11].
GluK2 mutations have been implicated previously in neuronal diseases
[61,71,72] but not in glucose homeostasis. Hints for a putative link to
diabetes may be given by reports of strongly decreased retinal GluK2
expression in streptozotocin-induced diabetes in rats [73] and GWAS
based association between a polymorphism near the GluK2 gene GRIK2
and diabetic retinopathy in man [74]. Interestingly, several features of the
phenotype observed here in GluK2/ mice resembled to some extent
experiments interfering with glucagon receptor activity or a-cell function
[75e78]. The underlying scenario would be given by the lower levels of
the hyperglycemic hormone glucagon and ensuing lesser needs of in-
sulin in line with the lower levels of insulin during GTT and fasting
glucagonwhich we observed here. In the long run, this would also lead to
improved insulin sensitivity as measured here. The conservation of in-
sulin sensitivity in middle-aged mice provides also the probable cause of
the improved outcome in the pyruvate challenge tests in those animals as
the latter was not altered in adult animals when insulin sensitivity was
still comparable between Gluk2þ/þ and Gluk2/ mice.
The improvement in islet function in terms of electrical activity and
insulin secretion represents most likely an adaptive mechanism to the
overall metabolic situation: a decreased demand on b-cell activity due
to lower basal glucagon levels and, in middle-aged animals, addi-
tionally due to a conserved insulin sensitivity. Our data also suggest
that these adaptive phenomena appear rather early, prior to differ-
ences in insulin sensitivity, as we observed increased glucose-induced
electrical b-cell activity in vitro already in adult GluK2/mice. A direct
effect on b-cells of lower a-cell derived glutamate or glucagon levels is
rather unlikely. As both, glutamate and glucagon, stimulate insulin
secretion in vitro [25,79], their reduction should lead to lower insulin
secretion whereas an enhancement was observed here.
5. CONCLUSION
Collectively, our observations suggest that kainate receptors are
implicated in glucose homeostasis, although the main initial mecha-
nism may imply several sites. Moreover, our data suggest that the
knockout of GluK2 may avoid the reduction in glucose homeostasis
that is known to occur during aging [80]. This obviously comes at the
cost of an increased risk of hypoglycemia, as evidenced here by the
marked lowering in glucose levels during the insulin sensitivity test in
GluK2/ middle-aged animals. The glutamate/glucagon feedback
loop may have provided an evolutionary advantage when food was
scarce, and its blockade may be of interest in the modern situation
often characterized by hypercaloric food supply. In this context, a
detailed profiling of novel kainate-receptor antagonists [81] on glucose
homeostasis and a-cell function could be of interest.158 MOLECULAR METABOLISM 30 (2019) 152e160  2019 The Authors. Published by Elsevier GmbH. TFUNDING
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